Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hangzhou Tigermed's score of 27 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Hangzhou Tigermed Consulting Co., Ltd. reported total carbon emissions of approximately 2,136,860 kg CO2e. This figure includes about 94,270 kg CO2e from Scope 1 emissions and approximately 2,042,580 kg CO2e from Scope 2 emissions. Compared to 2022, where total emissions were about 2,163,020 kg CO2e, the company has achieved a slight reduction in overall emissions. Tigermed has committed to near-term climate targets, although specific reduction targets have not been disclosed. The company has not yet committed to a net-zero target. Their emissions data indicates a focus on reducing Scope 1 and Scope 2 emissions, which are directly related to their operations and energy consumption. As a player in the Pharmaceuticals, Biotechnology, and Life Sciences sector, Tigermed's climate commitments align with industry standards, reflecting a growing emphasis on sustainability and environmental responsibility. The company continues to monitor and report its emissions, demonstrating a commitment to transparency in its climate impact.
Access structured emissions data, company-specific emission factors, and source documents
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|
Scope 1 | 63,180,000 | 00,000,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
Scope 2 | 1,037,878,000 | 0,000,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | - | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hangzhou Tigermed is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.